Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05198245 · ClinicalTrials.gov registry record
Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
A clinical trial of Migraine, sponsored by Pfizer.
- Active
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT05198245: Active study of Migraine, sponsored by Pfizer.
NCT05198245 is a study of Migraine that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 1 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05198245, a study of Migraine, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.
Conditions Studied
Interventions
- OTHER No intervention
- DRUG Rimegepant
- DRUG Various
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2028-04-17 |
What the registry record for NCT05198245 still lists
NCT05198245 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 3 interventions - of which No intervention is the first listed.
NCT05198245 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05198245 about?
NCT05198245 is a clinical study titled "Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy". The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.
What is the current status of trial NCT05198245?
This trial is currently active not recruiting. The enrollment target is 1 participants. The study started on 2021-12-15. Estimated completion is 2028-04-17.
What conditions does trial NCT05198245 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05198245?
The interventions under investigation include: No intervention (OTHER), Rimegepant (DRUG), Various (DRUG).
Who is sponsoring clinical trial NCT05198245?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05198245 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05198245's enrollment target sits among peer trials
1 103rd of 102 the lowest of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI